ClinicalTrials.gg
RecruitingNCT04879329Updated Jul 22, 2026

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

A Phase 2 interventional study of disitamab vedotin and pembrolizumab in Urothelial Carcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Recruiting at 221 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell — 5 open to participants now, 6 under way, 2 of them phase 3. disitamab vedotin · Carcinoma, Transitional Cell.

Planned enrollment
3rd of 10
372 · median 40
Started
2022
with 2 others
Phase 2
6 of 10
3 open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Seagen, a wholly owned subsidiary of Pfizer

Among the 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 2, and was the 5th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

5 of the 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About disitamab vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

03

Conditions studied

  • Urothelial Carcinoma

Keywords

  • Urothelial Cancer
  • Bladder Cancer
  • HER2 Mutations
  • HER2 Overexpression
  • HER2 Amplification
  • RC48
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohorts A and B

  • Histopathologically-confirmed, locally-advanced, unresectable or urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra
  • Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy
  • At least one by investigator assessment based on version 1.1.
  • -expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
  • (ECOG) performance status score of 0 or 1

Cohort C

  • Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
  • No prior systemic therapy for LA/mUC

    • or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy
  • At least one measurable lesion by investigator assessment based on RECIST v1.1.
  • Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation
  • HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample
  • ECOG performance status of 0, 1, or 2

Cohort D

  • Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
  • Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following for LA/mUC:

    • a. One prior line of platinum-containing chemotherapy.
    • b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment.
    • c. Prior enfortumab vedotin therapy.
  • At least one measurable lesion by investigator assessment based on RECIST v1.1.
  • ECOG performance status of 0 or 1

Cohort E

  • Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
  • No prior systemic therapy for LA/mUC

    • Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy.
  • At least one measurable lesion by investigator assessment based on RECIST v1.1.
  • Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation
  • HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
  • ECOG performance status of 0 or 1

Cohort G

  • Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra
  • Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of therapy containing enfortumab vedotin as monotherapy or in combination with pembrolizumab

    • The last administration of enfortumab vedotin must be 90 days from the start of study treatment. Intervening therapies are allowed between the final dose of enfortumab vedotin and the start of disitamab vedotin.
  • At least one measurable lesion by investigator assessment based on RECIST version 1.1.
  • HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

Cohorts A and B

  • Known to disitamab vedotin or any of their components
  • Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B)
  • Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
  • Prior MMAE-based ADCs (eg, enfortumab vedotin) or -directed therapy
  • Major surgery that has not fully recovered within 4 weeks prior to dose administration
  • Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline

Cohort C

  • Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components
  • Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C)
  • Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
  • Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy
  • Major surgery that has not fully recovered within 4 weeks prior to dose administration
  • Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study drug
  • Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, inhibitors, or OX-40 agonists) are excluded.

Cohort D

  • Known hypersensitivity to disitamab vedotin or any of their components
  • Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort D)
  • Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
  • Prior HER2-directed therapy
  • Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy
  • Major surgery that has not fully recovered within 4 weeks prior to dose administration
  • Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline

Cohort E

  • Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components
  • Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort E)
  • Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
  • Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy
  • Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy
  • Major surgery that has not fully recovered within 4 weeks prior to dose administration
  • Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug

Cohort G

  • Known hypersensitivity to disitamab vedotin or any of their components
  • Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort G)
  • Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
  • Prior HER2-directed therapy
  • Major surgery that has not fully recovered within 4 weeks prior to dose administration
  • Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
372 participants (estimated)

Study arms

  • Experimental
    Cohort A - DV monotherapy for HER2-positive tumor types

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

  • Experimental
    Cohort B - DV monotherapy for HER2-low tumor types

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

  • Experimental
    Cohort C - Non-randomized combination therapy

    Disitamab vedotin + pembrolizumab

    Drug: disitamab vedotin · Drug: pembrolizumab

  • Experimental
    Cohort C - Randomized combination therapy

    Disitamab vedotin + pembrolizumab

    Drug: disitamab vedotin · Drug: pembrolizumab

  • Experimental
    Cohort C - Randomized monotherapy

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

  • Experimental
    Cohort D - DV monotherapy (Japan only)

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

  • Experimental
    Cohort E - DV combination therapy (Japan only)

    Disitamab vedotin + pembrolizumab

    Drug: disitamab vedotin · Drug: pembrolizumab

  • Experimental
    Cohort G - DV monotherapy

    Disitamab vedotin

    Drug: disitamab vedotin

Interventions

  • Given into the vein (IV; intravenous) every 2 weeks.

    Also known as: RC48-ADC

  • Given by IV on Day 1 of each 6-week cycle.

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G)

    The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1

    Time frame: Duration of treatment; approximately 2 years

  2. Incidence of adverse events (AEs) (Cohorts D and E)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Approximately 2 years

  3. Incidence of dose alterations (Cohorts D and E)

    Time frame: Approximately 2 years

  4. Incidence of laboratory abnormalities (Cohorts D and E)

    To be summarized using descriptive statistics.

    Time frame: Approximately 2 years

  5. Incidence of electrocardiogram (ECG) abnormalities (Cohorts D and E)

    Time frame: Approximately 2 years

  6. Change from baseline of left ventricular ejection fraction (LVEF) (Cohorts D and E)

    Time frame: Approximately 2 years

  7. Pharmacokinetic (PK) parameter - Area under the curve (AUC) (Cohorts D and E)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  8. PK parameter - Maximum concentration (Cmax) (Cohorts D and E)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  9. PK parameter - Time to maximum concentration (Tmax) (Cohorts D and E)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  10. PK parameter - Trough concentration (Ctrough) (Cohorts D and E)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

Secondary outcomes

  1. cORR per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)

    The proportion of participants with confirmed CR or PR according to RECIST v1.1

    Time frame: Duration of treatment; approximately 2 years

  2. Confirmed Duration of Response (DOR) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)

    The time from first documentation of objective tumor response (confirmed CR or PR) to the first documentation of tumor progression per RECIST v1.1 or death due to any cause.

    Time frame: From start of treatment to completion of response assessment; approximately 2 years

  3. Confirmed DOR per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)

    The time from first documentation of objective tumor response (confirmed CR or PR) to the first documentation of tumor progression per RECIST v1.1 or death due to any cause.

    Time frame: From start of treatment to completion of response assessment; approximately 2 years

  4. Progression-free survival (PFS) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)

    The time from the start of study treatment or randomization (if applicable) to the first documentation of disease progression per RECIST v1.1 or death due to any cause.

    Time frame: From start of treatment to completion of response assessment; approximately 2 years

  5. PFS per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)

    The time from the start of study treatment or randomization (if applicable) to the first documentation of disease progression per RECIST v1.1 or death due to any cause.

    Time frame: From start of treatment to completion of response assessment; approximately 2 years

  6. Disease control rate (DCR) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)

    The proportion of participants who have achieved objective response (confirmed CR or PR as per RECIST v1.1 criteria) or stable disease (SD) lasting at least 5 weeks.

    Time frame: From start of treatment to completion of response assessment; approximately 2 years

  7. DCR per RECIST v1.1 by investigator (Cohorts A, B, C, and G)

    The proportion of participants who have achieved objective response (confirmed CR or PR as per RECIST v 1.1 criteria) or SD lasting at least 5 weeks.

    Time frame: From start of treatment to completion of response assessment; approximately 2 years

  8. Overall survival (OS) (Cohorts A, B, C, and G)

    The time from start of study treatment or randomization (if applicable) to the date of death due to any cause.

    Time frame: Duration of study; approximately 3 years

  9. Incidence of adverse events (AEs) (Cohorts A, B, C, and G)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Approximately 2 years

  10. Incidence of dose alterations (Cohorts A, B, C, and G)

    To be summarized using descriptive statistics.

    Time frame: Approximately 2 years

  11. Incidence of laboratory abnormalities (Cohorts A, B, C, and G)

    To be summarized using descriptive statistics.

    Time frame: Approximately 2 years

  12. Incidence of ECG abnormalities (Cohorts A, B, C, and G)

    Time frame: Approximately 2 years

  13. Change from baseline of LVEF (Cohorts A, B, C, and G)

    Time frame: Approximately 2 years

  14. PK parameter - AUC (Cohorts A, B, C, and G)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  15. PK parameter - Cmax (Cohorts A, B, C, and G)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  16. PK parameter - Tmax (Cohorts A, B, C, and G)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  17. PK parameter - Ctrough (Cohorts A, B, C, and G)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  18. PK parameter of pembrolizumab - Cmax (Cohort E)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  19. Incidence of anti-drug antibodies (ADAs) against disitamab vedotin (All Cohorts)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  20. Incidence of anti-drug antibodies (ADAs) against pembrolizumab (Cohorts C and E)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

  21. Incidence of neutralizing antibodies (NABs) against disitamab vedotin (All Cohorts)

    To be summarized using descriptive statistics.

    Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

07

Study locations

169 of 221 sites recruiting
  • Banner Gateway Medical Center
    Gilbert, Arizona 85234, United States
    Recruiting
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
    Recruiting
  • Kaiser Permanente Anaheim Kraemer Medical Offices
    Anaheim, California 92806, United States
    Recruiting
  • Foothill Cardioology
    Arcadia, California 91007, United States
    Recruiting
  • Kaiser Permanente Baldwin Park Medical Center
    Baldwin Park, California 91706, United States
    Recruiting
  • Kaiser Permanente Bellflower Medical Offices
    Bellflower, California 90706, United States
    Recruiting
  • Beverly Hills Multi-Specialties Practice
    Beverly Hills, California 90211, United States
    Recruiting
  • Providence Saint Joseph Medical Center
    Burbank, California 91505, United States
    Recruiting
  • UCLA Burbank Cardiology
    Burbank, California 91505, United States
    Recruiting
  • UCLA Hematology/Oncology - Burbank
    Burbank, California 91505, United States
    Recruiting
  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
    Duarte, California 91010, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UCLA Encino Specialty Care (Radiology)
    Encino, California 91436, United States
    Recruiting
  • UCLA Hematology/Oncoclogy-Encino
    Encino, California 91436, United States
    Recruiting
  • Kaiser Permanente Fontana Medical Center
    Fontana, California 92335, United States
    Recruiting
  • Foothill Cardiology Glendora
    Glendora, California 91741, United States
    Recruiting
  • Kaiser Permanente South Bay Medical center
    Harbor City, California 90710, United States
    Recruiting
  • Chao Family Comprehensive Cancer Center and Ambulatory Care
    Irvine, California 92612, United States
    Recruiting
  • Kaiser Permanente Alton/Sand Canyon Medical Offices
    Irvine, California 92618, United States
    Recruiting
  • UCLA Downtown Los Angeles Primary & Specialty Care
    Los Angeles, California 90017, United States
    Recruiting
  • Kaiser Permanente Los Angeles Medical Offices
    Los Angeles, California 90027, United States
    Recruiting
  • Kaiser Permanente West Los Angeles Medical Center
    Los Angeles, California 90034, United States
    Recruiting
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
    Not yet recruiting
  • Ronald Reagan UCLA Medical Center, Drug Information Center
    Los Angeles, California 90095, United States
    Recruiting
  • UCLA Cardiovascular Center
    Los Angeles, California 90095, United States
    Recruiting
  • UCLA Hematology Oncology
    Los Angeles, California 90095, United States
    Recruiting
  • UCLA Westwood Specialty Care
    Los Angeles, California 90095, United States
    Recruiting
  • UCLA Santa Monica Cardiology
    Los Angeles, California 90404, United States
    Recruiting
  • UCLA Montecito Primary & Specialty Care
    Montecito, California 93108, United States
    Recruiting
  • Newport Diagnostics Center (Radiology)
    Newport Beach, California 92660, United States
    Recruiting
  • Kaiser Permanente Ontario Medical Center
    Ontario, California 91761, United States
    Recruiting
  • UC Irvine Health
    Orange, California 92868, United States
    Recruiting
  • Kaiser Permanente Panorama City Medical Center, Medical Offices 3
    Panorama City, California 91402, United States
    Recruiting
  • Foothill Cardiology Pasadena
    Pasadena, California 91105, United States
    Recruiting
  • Southern California Heart Specialists
    Pasadena, California 91105, United States
    Recruiting
  • UCLA Hematology/ Oncology- Pasadena
    Pasadena, California 91105, United States
    Recruiting
  • UCLA Hematology Oncology - Porter Ranch
    Porter Ranch, California 91326, United States
    Recruiting
  • UCLA Porter Ranch Primary & Specialty Care
    Porter Ranch, California 91326, United States
    Recruiting
  • Kaiser Permanente Riverside Medical Center
    Riverside, California 92505, United States
    Recruiting
  • Southern California Permanente Medical Group (SCPMG)
    Riverside, California 92505, United States
    Recruiting
  • Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies)
    San Diego, California 92108, United States
    Recruiting
  • Kaiser Permanente Zion Medical Center
    San Diego, California 92120, United States
    Recruiting
  • UCSF Cancer Center MZ Phlebotomy
    San Francisco, California 94115, United States
    Recruiting
  • UCSF Mount Zion Phlebotomy
    San Francisco, California 94115, United States
    Recruiting
  • UCSF Parnassus Phlebotomy
    San Francisco, California 94143, United States
    Recruiting
  • UCSF Investigational Drugs Pharmacy
    San Francisco, California 94158, United States
    Recruiting
  • University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
    San Francisco, California 94158, United States
    Recruiting
  • University of California, San Francisco
    San Francisco, California 94158, United States
    Recruiting
  • Diagnostic Medical Group of Southern California (Radiology)
    San Gabriel, California 91776, United States
    Recruiting
  • Southern California Heart Centers
    San Gabriel, California 91776, United States
    Recruiting
  • UCLA Hematology/Oncology - San Luis Obispo
    San Luis Obispo, California 93401, United States
    Recruiting
  • Sierra Vista Regional Medical Center
    San Luis Obispo, California 93405, United States
    Recruiting
  • Kaiser Permanente San Marcos Medical Offices
    San Marcos, California 92078, United States
    Recruiting
  • UCLA Hematology/Oncology - Santa Monica
    Santa Monica, California 90404, United States
    Recruiting
  • UCLA Simi Valley Alamo Specialty Care
    Simi Valley, California 93065, United States
    Recruiting
  • Twin Cities Community Hospital
    Templeton, California 93465, United States
    Recruiting
  • UCLA Thousand Oaks Primary & Specialty Care
    Thousand Oaks, California 91360, United States
    Recruiting
  • UCLA Hematology/Oncology - Torrance
    Torrance, California 90505, United States
    Recruiting
  • UCLA Torrance Lomita Specialty Care
    Torrance, California 90505, United States
    Recruiting
  • UCLA Hematology-Oncology Clinic - Santa Clarita
    Valencia, California 91355, United States
    Recruiting
  • UCLA Santa Clarita Primary & Specialty Care
    Valencia, California 91355, United States
    Recruiting
  • UCLA Hematology/Oncology - Ventura
    Ventura, California 93003, United States
    Recruiting
  • UCLA Ventura Cardiology
    Ventura, California 93003, United States
    Recruiting
  • UCLA Hematology/Oncology - Westlake
    Westlake Village, California 91361, United States
    Recruiting
  • Kaiser Permanente Woodland Hills Medical Center
    Woodland Hills, California 91367, United States
    Recruiting
  • Medstar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Florida Cancer Specialists
    Bonita Springs, Florida 34135, United States
    Recruiting
  • Florida Cancer Specialists
    Bradenton, Florida 34205, United States
    Recruiting
  • Florida Cancer Specialists
    Bradenton, Florida 34211, United States
    Recruiting
  • Florida Cancer Specialists
    Cape Coral, Florida 33909, United States
    Recruiting
  • Florida Cancer Specialists
    Daytona Beach, Florida 32117, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Florida Cancer Specialists
    Fleming Island, Florida 32003, United States
    Recruiting
  • Florida Cancer Specialists
    Fort Myers, Florida 33905, United States
    Recruiting
  • Florida Cancer Specialists
    Fort Myers, Florida 33908, United States
    Recruiting
  • Florida Cancer Specialists
    N. Venice, Florida 34275, United States
    Recruiting
  • Florida Cancer Specialists
    Naples, Florida 34102, United States
    Recruiting
  • Florida Cancer Specialists
    Port Charlotte, Florida 33980, United States
    Recruiting
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
    Recruiting
  • Florida Cancer Specialists Sarasota Memorial Hospital (SAD)
    Sarasota, Florida 34239, United States
    Recruiting
  • Florida Cancer Specialists
    Stuart, Florida 34994, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Florida Cancer Specialists
    Tallahassee, Florida 32308, United States
    Recruiting
  • Moffitt Cancer Center McKinley Hospital
    Tampa, Florida 33612, United States
    Recruiting
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
  • Florida Cancer Specialists
    Venice, Florida 34285, United States
    Recruiting
  • Florida Cancer Specialists
    Venice, Florida 34292, United States
    Recruiting
  • Florida Cancer Specialists
    Vero Beach, Florida 32960, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Florida Cancer Specialists
    Wellington, Florida 33414, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica
    Carrollton, Georgia 30117, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica
    Carrollton, Georgia 30117, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
    Cartersville, Georgia 30121, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
    Douglasville, Georgia 30134, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
    Hiram, Georgia 30141, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • WellStar Paulding Hospital
    Hiram, Georgia 30141, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
    Marietta, Georgia 30060, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UChicago Medicine - River East
    Chicago, Illinois 60611, United States
    Recruiting
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
  • Accellacare - Deerfield
    Deerfield, Illinois 60015, United States
    Recruiting
  • UChicago Medicine at Ingalls - Flossmoor
    Flossmoor, Illinois 60422, United States
    Recruiting
  • UChicago Medicine Ingalls Memorial
    Harvey, Illinois 60426, United States
    Recruiting
  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
    New Lenox, Illinois 60451, United States
    Recruiting

Showing the first 100 of 221 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's planned 55 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
May 10, 2021
StartActual
May 3, 2022
Primary completionEst.
Dec 11, 2026
CompletionEst.
Apr 14, 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04879329
Responsible party
Sponsor
First posted
May 10, 2021
Start date
May 3, 2022
Primary completion
Dec 11, 2026 (estimated)
Completion
Apr 14, 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion